Abstract
The molecular medicine revolution has resulted in a more complete understanding about the etiology and pathophysiology of a variety of illnesses. This remarkable progress reflects in large part the elucidation of the basic mechanisms of signal transduction, and the application of the powerful tools of molecular biology to the study of human disease. Although we have yet to identify the speci&c abnormal genes in mood disorders, recent studies have implicated signal transduction pathways, in particular the stimulatory guanine nucleotide binding protein (Gs)/cyclic AMP and protein kinase C pathways, in the pathophysiology and treatment of mood disorders. Recent studies have also shown that mood stabilizers exert neurotrophic and neuroprotective effects not only in preclinical paradigms, but also in humans. Together, these studies suggest that mood disorders may be associated with impaired neuroplasticity and cellular resiliency, &ndings that may have major implications for our understanding of mood disorders, and for the development of improved therapeutics.
Similar content being viewed by others
References and Recommended Reading
Weintraub BD: Molecular Endocrinology: Basic Concepts and Clinical Correlations. New York: Raven Press; 1995.
Spiegel AM: G Proteins, receptors, and disease. Totowa, NJ: Humana Press; 1998.
Goodwin FK, Jamison KR: Manic-Depressive Illness. New York: Oxford University Press; 1990.
Manji HK, Potter WZ: Monoaminergic mechanisms. In Bipolar Disorder: Biological Models and their Clinical Application. Edited by Joffe RT, Young LT. New York: Marcel Dekker; 1997:1–40.
Schatzberg AF, Schildkraut JJ: Recent studies on norepinephrine systems in mood disorders. In Psychopharmacology: The Fourth Generation of Progress. Edited by Bloom FE, Kupfer DJ. New York: Raven Press; 1995:911–920.
Willner P: Dopaminergic mechanisms in depression and mania. In Psychopharmacology: The Fourth Generation of Progress. Edited by Bloom FE, Kupfer DJ. New York: Raven Press; 1995:921–931.
Maes M, Meltzer HY: The serotonin hypothesis of major depression. In Psychopharmacology: The Fourth Generation of Progrss. Edited by Bloom FE, Kupfer DJ. New York: Raven Press; 1995:933–944.
Garlow SJ, Musselman DL, Nemeroff CB: The neurochemistry of mood disorders clinical studies. In Neurobiology of Mental Illness. Edited by Charney DS, Nester EJ, Bunney BS. New York: Oxford University Press; 1999:348–364.
Janowsky DS, Overstreet DH. The role of acetylcholine mechanisms in mood disorders. In Psychopharmacology: The Fourth Generation of Progress. Edited by Bloom FE, Kupfer J. New York: Raven Press; 1995:945–956.
Hudson CJ, Young LT, Li PP, Warsh JJ: CNS signal transduction in the patho-physiology and pharmacotherapy of affective disorders and schizophrenia. Synapse 1993, 13:278–293.
CL: Toward an integrated biological model of bipolar disorder. In Bipolar Disorder: Biological Models and Their Clinical Application. Edited by Young LT, Joffe RT. New York: Marcel Dekker; 1997:235–254.
Manji HK, Chen G, Hsiao JK, et al.: Regulation of signal transduction pathways by mood stabilizing agents: implications for the pathophysiology and treatment of bipolar affective disorder. In Bipolar Medications: Mechanisms of Action. Edited by Manji HK, Bowden CL, Belmaker RH. Washington: American Psychiatric Press; 2000a:129–177.
Manji HK, Chen G, Shimon H, et al.: Guanine nucleotide binding proteins in bipolar affective disorder: effects of long-term lithium treatment. Arch Gen Psych 1995a, 52:135–144.
Manji HK, Potter WZ, Lenox RH: Signal transduction pathways: molecular targets for lithium’s actions. Arch Gen Psych 1995b, 52:531–543.
Wang JF, Young LT, Li PP, Warsh JJ: Signal transduction abnormalities in bipolar disorder. In Bipolar Disorder: Biological Models and their Clinical Application. Edited by Joffe RT, Young LT. New York: Marcel Dekker; 1997:41–79.
Post RM, Weiss SRB, Clark M, et al.: Lithium, carbamazepine, and valproate in affective illness: biochemical and neurobiological mechanisms. In Bipolar Medications: Mechanisms of Action. Edited by Manji HK, Bowden CL, Belmaker RH. Washington: American Psychiatric Press; 2000:219–248.
Warsh JJ, Young LT, Li PP: Guanine nucleotide binding (G) protein disturbances in bipolar affective disorder. In Bipolar Medications: Mechanisms of Action. Edited by Manji HK, Bowden CL, Belmaker RH. Washington: American Psychiatric Press; 2000:299–329.
Bourne HR, Nicoll R: Molecular machines integrate coincident synaptic signals. Cell Supp 1993, 72:65–75.
Bhalla US, Iyengar R: Emergent properties of networks of biological signaling pathways. Science 1999, 283:381–387. This paper describes the networks that signaling proteins form, and there importance for regulating complex biologic systems.
Weng G, Bhalla US, Iyengar R: Complexity in biological signaling systems. Science 1999, 284:92–96.
Manji HK: G proteins: implications for psychiatry. Am J Psychiatry 1992, 149:746–760.
Milligan G, Wakelam M: G Proteins: Signal Transduction & Disease. San Diego, CA: Academic Press; 1992.
Weinstein LS: Alteration of G protein expression or function in pathophysiology. In G Proteins. Edited by Spiegel AM, Jones TLZ, Simonds WF, Weinstein LS. Georgetown, TX: RG Landes Company; 1994:118–128.
Schreiber G, Avissar S, Danon A, Belmaker RH: Hyperfunctional G proteins in mononuclear leukocytes of patients with mania. Biol Psychiatry 1991, 29:273–80.
Young LT, Li PP, Kish SJ, et al.: Cerebral cortex Gs a protein levels and forskolin-stimulated cyclic AMP formation are increased in bipolar affective disorder. J Neurochem 1993, 61:890–898.
Mitchell PB, Manji HK, Chen G, et al.: Increased levels of Gas in platelets of euthymic bipolar affective disorder patients. Am J Psych 1997, 154:218–223.
Garcia-Sevilla JA, Walzer C, Busquets X, et al.: Density of guanine nucleotide-binding proteins in platelets of patients with major depression: increased abundance of the G alpha i2 subunit and down-regulation by antidepressant drug treatment. Biol Psych 1997, 42:704–712.
Garcia-Sevilla JA, Escriba PV, Ozaita A, et al.: Up-regulation of immunolabeled alpha2A-adrenoceptors, Gi coupling proteins, and regulatory receptor kinases in the prefrontal cortex of depressed suicides. J Neurochem 1999, 72:282–291.
Spleiss O, van Calker D, Scharer L, et al.: Abnormal G protein alpha(s)-and alpha(i2)-subunit mRNA expression in bipolar affective disorder. Mol Psych 1998, 3:512–520.
Li PP, Andreopoulos S, Warsh JJ: Signal transduction abnormalities in bipolar affective disorder. In Cerbral Signal. Edited by Reith MEA. New Jersey: Humana Press; 2000:283–312.
Wang HY, Friedman E: Enhanced protein kinase C activity and translocation in bipolar affective disorder brains. Biol Psych 1996, 40:568–575.
Ram A, Guedj F, Cravchik A, et al.: No abnormality in the gene for the G protein stimulatory a subunit in patients with bipolar disorder. Arch Gen Psych 1997, 54:44–48.
Siever LJ: Role of noradrenergic mechanisms in the etiology of the affective disorders. In Psychopharmacology: The Third Generation of Progress. Edited by Meltzer HY. New York: Raven; 1987:493–504.
Mann JJ, Brown RP, Halper JP, et al.: Reduced sensitivity of lymphocyte beta-adrenergic receptors in patients with endogenous depression and psychomotor agitation. N Engl J Med 1985, 313:715–720.
Ebstein RP, Lerer B, Shapira B, et al.: Cyclic AMP second-messenger signal ampli&cation in depression. Br J Psychiatry 1988, 152:665–669.
Halper JP, Brown RP, Sweeney JA, et al.: Blunted beta-adrenergic responsivity of peripheral blood mononuclear cells in endogenous depression: isoproterenol dose response studies. Arch Gen Psych 1988, 45:241–244.
Mork A, Geisler A, Hollund P: Effects of lithium on second messenger systems in the brain. Pharmacol Toxicol 1992, 71:4–17.
Perez J, Tardito D, Mori S, et al.: Abnormalities of cAMP signaling in affective disorders: implications for pathophysiology and treatment. Bipolar Disord 2000, 2:27–36.
Rahman S, Li PP, Young LT, et al.: Reduced [3H] cyclic AMP binding in postmortem brain from subjects with bipolar affective disorder. J Neurochem 1997, 68:297–304.
&elds A, Li PP, Kish SJ, et al.: Increased cyclic AMP-dependent protein kinase activity in postmortem brain from patients with bipolar affective disorder. J Neurochem 1999, 73:1704–1710.
Jope RS: Anti-bipolar therapy: mechanism of action of lithium. Molecular Psychiatry 1999a, 4:117–128.
Risby ED, Hsiao JK, Manji HK, et al.: The mechanisms of action of lithium. Arch Gen Psych 1991, 48:513–524.
Wang HY, Friedman E: Effects of lithium on receptor-mediated activation of G proteins in rat brain cortical membranes. Neuropharmacology 1999, 38:403–414.
Manji HK, Lenox RH: Signaling: cellular insights into the pathophysiology of bipolar disorder. Biol Psych 2000, 48:518–530.
Jope RS: A bimodal model of the mechanism of action of lithium. Mol Psychiatry 1999b, 4:21–25.
Chen G, Masana M, Manji HK: Lithium regulates PKC-mediated intracellular cross-talk and gene expression in the CNS in vivo. Bipolar Disord 2000a, in press.
Ozaki N, Manji HK, Luiberman V, et al.: A naturally Occurring amino acid substitution of the human serotonin (5-HT) 2A receptor influences amplitude and timing of intracellular calcium mobilization. J Neurochem 1997, 68:2186–2193.
Wang JF, Asghari V, Rockel C, Young LT: Cyclic AMP responsive element binding protein phosphorylation and DNA binding is decreased by chronic lithium but not valproate treatment of SH-SY5Y neuroblastoma cells. Neuroscience 1999, 91:771–776.
Cowburn RF, Marcusson JO, Eriksson A, et al.: Adenylyl cyclase activity and G-protein subunit levels in postmortem frontal cortex of suicide victims. Brain Res 1994, 633:297–304.
Lowther S, Crompton MR. Katona CL, Horton RW: GTP gamma S and forskolin-stimulated adenylyl cyclase activity in post-mortem brain from depressed suicides and controls. Mol Psych 1996, 1:470–477.
Rasenick MM, Ozawa J, Chen H: Effects of antidepressant treatments on the G protein-adenylyl cyclase axis as the possible basis of therapeutic action. In Bipolar Medications: Mechanisms of Action. Edited by HK Manji, CL Bowden, RH Belmaker. Washington: American Psychiatric Press; 2000:87–108.
Nestler EJ, Terwilliger RZ, Duman RS: Chronic antidepressant administration alters the subcellular distribution of cyclic AMP-dependent protein kinase in rat frontal cortex. J Neurochem 1989, 53:1644–1647.
Popoli M, Brunello N, Perez J, Racagni G: Second messenger-regulated protein kinases in the brain: their functional role and the action of antidepressant drugs. J Neurochem 2000, 74:21–33.
Duman RS, Heninger GR, Nestler EJ: A molecular and cellular theory of depression. Arch Gen Psych 1997, 54:597–606.
Duman RS, Malberg K, Nakagawa S, D’Sa C: Neuronal plasticity and survival in mood disorders. Biol Psychiatry 2000, 48:732–739.
Dowlatshahi D, MacQueen GM, Wang JF, Young LT: Increased temporal cortex CREB concentrations and antidepressant treatment in major depression. Lancet 1998, 2352:1754–1755. This study examines the levels of the cyclic AMP responsive binding protein (CREB) in postmortem human brain. Depressed patients treated with antidepressants were demonstrated to have signi&cantly higher levels, providing support for similar observations in rodents.
Hahn CG, Friedman E. Abnormalities in protein kinase C signaling and the pathophysiology of bipolar disorder. Bipolar Disord 1999, 1:81–86.
Nishizuka Y: Protein kinase C and lipid signaling for sustained cellular responses. FASEB J 1995, 9:484–496.
Nishizuka Y: Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 1992, 258:607–614.
Stabel S, Parker PJ: Protein kinase C. Pharmacol Ther 1991, 51:71–95.
Newton AC: Protein kinase C: structure, function, and regulation. J Biol Chem 1995, 270:28495–28498.
Freidman E, Hoau YW, Levinson D, et al.: Altered platelet protein kinase C activity in bipolar affective disorder, manic episode. Biol Psychiatry 1993, 33:520–525.
Pandey GN, Dwivedi Y, Pandey SC, et al.: Protein kinase C in the postmortem brain of teenage suicide victims. Neurosci Lett 1997, 228:111–114.
Coull MA, Lowther S, Katona CL, Horton RW: Altered brain protein kinase C in depression: a post-mortem study. Eur Neuropsychopharmacol 2000, 10:283–288.
Manji HK, Lenox RH: Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of bipolar disorder. Biol Psych 1999, 46:1328–1351. This paper presents a hypothesis, supported by both preclinical and clinical evidence, that posits that the PKC signaling pathway plays a major role in the pathophysiology and treatment of bipolar disorder.
Manji HK, Etcheberrigaray R, Chen G, et al.: Lithium dramatically decreases membrane-associated PKC in the hippocampus: selectivity for the alpha isozyme. J Neurochem 1993, 61:2303–2310.
Lenox RH, Watson DGJP, Ellis J: Chronic lithium administration alters a prominent PKC substrate in rat hippocampus. Brain Res 1992, 570:333–340.
Chen G, Manji HK, Hawver DB, et al.: Chronic sodium valproate selectively decreases protein kinase C a and e in vitro. J Neurochem 1994, 63:2361–2364.
Watson DG, Watterson JM, Lenox RH: Sodium valproate down-regulates the myristoylated alanine-rich C kinase substrate (MARCKS) in immortalized hippocampal cells: a property of protein kinase C-mediated mood stabilizers. J Pharmacol Exp Ther 1998, 285:307–316.
Lenox RH, McNamara RK, Watson DG: A molecular target for the long-term action of lithium in the brain: a phosphoprotein substrate of protein kinase C. In Bipolar Medications: Mechanisms of Action. Edited by Manji HK, Bowden CL, Belmaker RH. Washington: American Psychiatric Press; 2000:197–218.
Conn PJ, Sweatt JD: Protein kinase C in the nervous system. In Protein Kinase C. Edited by Kuo JF. New York: Oxford University Press; 1994:199–235.
Couldwell WT, Weiss MH, DeGiorgio CM, et al.: Clinical and radiographic response in patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery 1993, 32:485–489.
Bebchuk JM, Arfken CL, Dolan-Manji S, et al.: A preliminary investigation of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania. Arch Gen Psychiatry 2000, 57:95–97.
Dubovsky S, Murphy J, Christiano J, et al.: The calcium second messenger system in bipolar disorders: Data supporting new research directions. J Neuropsych 1992, 4:3–14.
Emamghoreishi M, Schlichter L, Li PP, et al.: High intracellular calcium concentrations in transformed lymphoblasts from subjects with bipolar I disorder. Am J Psychiatry 1997, 154:976–82.
Hough C, Lu SJ, Davis CL, et al.: Elevated basal and thapsigargin stimulated intracellular calcium of platelets and lymphocytes from bipolar affective disorder patients measured by a fluorometric microassay. Biol Psychiatry 1999, 46:247–255.
Magnier C, Corvazier E, Aumont MC, et al.: Relationship between Rap1 protein phosphorylation and regulation of Ca2+ transport in platelets: a new approach. Biochem J 1995, 310:4694–75.
Drevets WC, Gadde KM, Krishnan KRR: Neuroimaging studies of mood disorders. In Neurobiology of Mental Illness. Edited by Charney DS, Nestler EJ, Bunney BS. New York: Oxford University Press; 1999:394–418.
Manji HK, Moore GJ, Rajkowska G, Chen G: Neuroplasticity and cellular resilience in mood disorders. Millennium Article. Mol Psych 2000b, in press.
Rajkowska G: Histopathology of the prefrontal cortex in depression: what does it tell us about dysfunctional monoaminergic circuits. Prog Brain Res 2000, 126:397–412.
Post RM, Weiss SRB: Neurobiological models of recurrence in mood disorder. In Neurobiology of Mental Illness. Edited by Charney DS, Nester EJ, Bunney BS. New York: Oxford University Press; 1999:365–384.
Manji HK, Moore GJ, Chen G: Lithium at 50: have the neuroprotective effects of this unique cation been overlooked? Biol Psych 1999, 46:929–940.
Chen G, Zeng WZ, Jiang L, et al.: The mood stabilizing agents lithium and valproate robustly increase the expression of the neuroprotective protein bcl-2 in the CNS. J Neurochem 1999b, 72:879–882. This paper describes a series of mRNA RT-PCR studies which led to a hitherto completely unexpected target for the actions of chronic lithium and valproate, the major cytoprotective protein, bcl-2.
Chen RW, Chuang DM: Long term lithium treatment suppresses p53 and Bax expression but increases bcl-2 expression. J Biol Chem 1999, 274:6039–6042.
Nonaka S, Chuang DM: Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats. Neuroreport 1998, 9:2081–2084.
Chen G, Rajkowska G, Du F, et al.: Enhancement of Hippocampal Neurogenesis by Lithium. J Neurochem 2000b, 75:1729–1734. oThis study utilizes bromodeoxyuridine (BrdU), a thymidine analog that labels the DNA of dividing cells, to demonstrate that chronic lithium enhances neurogenesis in the adult mammalian neurogenesis.
Moore GJ, Bebchuk JM, Hasanat K, et al.: Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2′s neurotrophic effects? Biol Psych 2000a, 48:1–8.
Moore GJ, Wilds IB, Bebchuk JM, et al.: Lithium increases gray matter in bipolar disorder. Lancet 2000b, 356:1241–1242. This study utilized quantitative three-dimensional MRI in a longitudinal study of bipolar disorder subjects, to investigate putative neurotrophic effects of lithium. This study revealed the extraordinary &nding that lithium produces small but signi&cant increases in gray matter volumes in humans.
Nestler EJ: Antidepressant treatments in the 21st century. Biol Psych 1998, 44:526–533.
Guo Z, Zhou D, Schultz PG: Designing small-molecule switches for protein-protein interactions. Science 2000, 288:2042–2045. This paper described the recent progress that has been made in developing chemical compounds to regulate signaling pathways via protein:protein interactions. The advances have considerable potential for the development of novel signal transduction modi&ers for the treatment of human diseases.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Manji, H.K., Chen, G. Post-receptor signaling pathways in the pathophysiology and treatment of mood disorders. Curr Psychiatry Rep 2, 479–489 (2000). https://doi.org/10.1007/s11920-000-0006-6
Issue Date:
DOI: https://doi.org/10.1007/s11920-000-0006-6